Tumors of female reproductive systemTumors of female reproductive systemОпухоли женской репродуктивной системы1994-40981999-8627Publishing House ABV Press12110.17650/1994-4098-2012-0-3-4-93-98GYNECOLOGY. DIAGNOSISГИНЕКОЛОГИЯ. ДИАГНОСТИКАQuantification analysis of the expression of tumor-associated proteins in serum samples from patients with ovarian cancer and those with other tumor location. Possibilities of their use in the diagnosis and estimation of the extent of a tumorous processКоличественный анализ экспрессии опухолеассоциированных белков в образцах сывороток крови у больных раком яичника и у больных с другой локализацией опухоли. Возможности использования для диагностики и оценки распространенности опухолевого процессаBobrovaT. S.БоброваТ. С.
Russian Federation
Omegov4763@mail.ruChuyevYu. V.ЧуевЮ. В.
Russian Federation
ZhordaniaK. I.ЖорданиаК. И.
Russian Federation
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, MoscowФГБУ «РОНЦ им. Н.Н. Блохина» РАМН, Москва240920123-4939824072014240720142012https://ojrs.abvpress.ru/ojrs/article/view/121

The specific features of the expression of tumor-associated proteins (TAP) were immunologically studied in the sera of patients with ovarian cancer (OC) and other tumor location by means of immune sera (As) or monoclonal antibodies (MAb) to find out whether they could be used to diagnose and estimate the extent of a tumorous process.MAb 1 (to HEp-2 cell membrane proteins, larynx cancer), Ac4 (to a pool of two ovarian cystadenocarcinomas), and MAb 3 (to affinity-pu- rified proteins of the apparently intact human gastric mucosa) were used to examine the sera of patients with OC and other tumor location and positive responsiveness was detected in 82, ~100, and 77 % of cases, respectively. The differences in the expression of TAP in the patients versus healthy donors were shown to be statistically significant (p = 0.0001; p = 0.015; p = 0.01, respectively).The sensitivity of quantifying ELISA in detecting TAP was 78 and 85 % in patients with Stages I–II and III–IV OC, respectively; ~100 and 89 % in patients with breast cancer and in those with gastrointestinal tract cancer, respectively; and 60 and 14 % in patients with lymphopro- liferative diseases and healthy donors, respectively. Comparison of TAP detection rates in the authors’ test systems with multiplex testing with a biochip array of 12 tumor markers has shown that these test systems are at the world standard level.

tumor-associated proteins, ELISA, ovarian cancer, cancer patients, serum, diagnosisопухоль-ассоциированные белкиELISAрак яичникаонкологические больныесыворотка кровидиагностика1. Жорданиа К.И. Злокачественные эпителиальные опухоли яичника. Совр Онкол 2000;2(2):51−5.Жорданиа К.И. Злокачественные эпителиальные опухоли яичника. Совр Онкол 2000;2(2):51−5.2. Кидралиев Р.Р., Адамян Л.В., Жорданиа К.И. и др. Лизофосфатидиловая кислота как биомаркер рака яичника. ОЖРС 2007;1−2:80−4.Кидралиев Р.Р., Адамян Л.В., Жорданиа К.И. и др. Лизофосфатидиловая кислота как биомаркер рака яичника. ОЖРС 2007;1−2:80−4.3. Сафронникова Н.Р. Профилактика и ранняя диагностика гинекологического рака. Материалы съезда онкологов и радиологов СНГ. Ч. I. Минск: ОДО Тонпик, 2004. С. 249−53.Сафронникова Н.Р. Профилактика и ранняя диагностика гинекологического рака. Материалы съезда онкологов и радиологов СНГ. Ч. I. Минск: ОДО Тонпик, 2004. С. 249−53.4. Atack D.B., Nisker J.A., Allen H.H. et al. CA-125 surveillance and second-look laparotomy in ovarian carcinoma Am J Obstet Gynecol 1986;154:287−9.Atack D.B., Nisker J.A., Allen H.H. et al. CA-125 surveillance and second-look laparotomy in ovarian carcinoma Am J Obstet Gynecol 1986;154:287−9.5. Bast R.C., Boyer C.M., Olt G.J. Ovarian cancer. Biological and therapeutic challenges London, 1991. Pp. 265−75.Bast R.C., Boyer C.M., Olt G.J. Ovarian cancer. Biological and therapeutic challenges London, 1991. Pp. 265−75.6. Borgono C.A., Grass L., Soosaipillai A. et al. Human kallikrein 14. A new potential biomarker for ovarian and breast cancer. Cancer Res 2003;63(24):9032−41.Borgono C.A., Grass L., Soosaipillai A. et al. Human kallikrein 14. A new potential biomarker for ovarian and breast cancer. Cancer Res 2003;63(24):9032−41.7. Luo L., Katsaros D., Scorilas A. et al. The serum concentration of human kallikrein 10 represents a novel biomarker for ovarian cancer diagnosis and prognosis. Cancer Res 2003;63(4):807−11.Luo L., Katsaros D., Scorilas A. et al. The serum concentration of human kallikrein 10 represents a novel biomarker for ovarian cancer diagnosis and prognosis. Cancer Res 2003;63(4):807−11.8. Skates S.J., Horick N., Yu Y. et al. Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA15-3, CA72-4, and macrophage colony-stimulating factor using mixtures of multivariate normal distribu- tions. J Clin Oncol 2004;22(20):4059−66.Skates S.J., Horick N., Yu Y. et al. Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA15-3, CA72-4, and macrophage colony-stimulating factor using mixtures of multivariate normal distribu- tions. J Clin Oncol 2004;22(20):4059−66.9. Wong N.K., Easton R.L., Panico M. et al. Characterization of the oligosaccharides associated with the human ovarian tumor marker CA125. J Biol Chem 2003;278(31): 28619−34.Wong N.K., Easton R.L., Panico M. et al. Characterization of the oligosaccharides associated with the human ovarian tumor marker CA125. J Biol Chem 2003;278(31): 28619−34.10. Zhang Z., Bast R.C., Yu Y. et al. Three biomarkers identified from serum proteomic analysis for detection of early stage ovarian carcer. Cancer Res 2004;64(16):5882−90.Zhang Z., Bast R.C., Yu Y. et al. Three biomarkers identified from serum proteomic analysis for detection of early stage ovarian carcer. Cancer Res 2004;64(16):5882−90.11. Боброва Т.С., Чуев Ю.В. Исследование опухоле-ассоциированных белков в тканях и сыворотках крови больных карциномами молочной железы. Мед иммунол 2006; 8(5−6):645−52.Боброва Т.С., Чуев Ю.В. Исследование опухоле-ассоциированных белков в тканях и сыворотках крови больных карциномами молочной железы. Мед иммунол 2006; 8(5−6):645−52.12. Боброва Т.С., Чуев Ю.В., Жорданиа К.И. Экспрессия опухоле-ассоциированных белков в тканях и сыворотках крови у больных раком яичника. ОЖРС 2008;1:65−72.Боброва Т.С., Чуев Ю.В., Жорданиа К.И. Экспрессия опухоле-ассоциированных белков в тканях и сыворотках крови у больных раком яичника. ОЖРС 2008;1:65−72.13. Закс Л. Статистическое оценивание. М.: Статистика, 1976; с. 129−53.Закс Л. Статистическое оценивание. М.: Статистика, 1976; с. 129−53.14. Sun Z., Fu X., Zhang L. A protein chip system for parallel analysis of multitumor markers and its application in cancer detection. Anticancer Res 2004;24:1159−66.Sun Z., Fu X., Zhang L. A protein chip system for parallel analysis of multitumor markers and its application in cancer detection. Anticancer Res 2004;24:1159−66.